151 related articles for article (PubMed ID: 36963361)
1. Autophagy orchestrates resistance in hepatocellular carcinoma cells.
Seydi H; Nouri K; Rezaei N; Tamimi A; Hassan M; Mirzaei H; Vosough M
Biomed Pharmacother; 2023 May; 161():114487. PubMed ID: 36963361
[TBL] [Abstract][Full Text] [Related]
2. Multifaceted role of NF-κB in hepatocellular carcinoma therapy: Molecular landscape, therapeutic compounds and nanomaterial approaches.
Gupta R; Kadhim MM; Turki Jalil A; Obayes AM; Aminov Z; Alsaikhan F; Ramírez-Coronel AA; Ramaiah P; Tayyib NA; Luo X
Environ Res; 2023 Jul; 228():115767. PubMed ID: 36966991
[TBL] [Abstract][Full Text] [Related]
3. Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis.
Shi YH; Ding ZB; Zhou J; Hui B; Shi GM; Ke AW; Wang XY; Dai Z; Peng YF; Gu CY; Qiu SJ; Fan J
Autophagy; 2011 Oct; 7(10):1159-72. PubMed ID: 21691147
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors promote epithelial-mesenchymal transition in Hepatocellular Carcinoma
Xiao Q; Liu H; Wang HS; Cao MT; Meng XJ; Xiang YL; Zhang YQ; Shu F; Zhang QG; Shan H; Jiang GM
Theranostics; 2020; 10(22):10245-10261. PubMed ID: 32929346
[TBL] [Abstract][Full Text] [Related]
5. MiR-25 enhances autophagy and promotes sorafenib resistance of hepatocellular carcinoma via targeting FBXW7.
Feng X; Zou B; Nan T; Zheng X; Zheng L; Lan J; Chen W; Yu J
Int J Med Sci; 2022; 19(2):257-266. PubMed ID: 35165511
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of eukaryotic translation initiation factor 5A2 enhances the therapeutic efficiency of doxorubicin in hepatocellular carcinoma cells by triggering lethal autophagy.
Tang Y; Chen K; Luan X; Zhang J; Liu R; Zheng X; Xie S; Ke H; Zhang X; Chen W
Int J Oncol; 2020 Dec; 57(6):1368-1380. PubMed ID: 33174013
[TBL] [Abstract][Full Text] [Related]
7. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
[TBL] [Abstract][Full Text] [Related]
8. Vaccinia-related kinase 2 blunts sorafenib's efficacy against hepatocellular carcinoma by disturbing the apoptosis-autophagy balance.
Chen S; Du Y; Xu B; Li Q; Yang L; Jiang Z; Zeng Z; Chen L
Oncogene; 2021 May; 40(19):3378-3393. PubMed ID: 33875785
[TBL] [Abstract][Full Text] [Related]
9. The role of the key autophagy kinase ULK1 in hepatocellular carcinoma and its validation as a treatment target.
Xue ST; Li K; Gao Y; Zhao LY; Gao Y; Yi H; Jiang JD; Li ZR
Autophagy; 2020 Oct; 16(10):1823-1837. PubMed ID: 31986961
[TBL] [Abstract][Full Text] [Related]
10. Cholesterol sensor SCAP contributes to sorafenib resistance by regulating autophagy in hepatocellular carcinoma.
Li D; Yao Y; Rao Y; Huang X; Wei L; You Z; Zheng G; Hou X; Su Y; Varghese Z; Moorhead JF; Chen Y; Ruan XZ
J Exp Clin Cancer Res; 2022 Mar; 41(1):116. PubMed ID: 35354475
[TBL] [Abstract][Full Text] [Related]
11. CD24 regulates sorafenib resistance via activating autophagy in hepatocellular carcinoma.
Lu S; Yao Y; Xu G; Zhou C; Zhang Y; Sun J; Jiang R; Shao Q; Chen Y
Cell Death Dis; 2018 May; 9(6):646. PubMed ID: 29844385
[TBL] [Abstract][Full Text] [Related]
12. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
Shimizu S; Takehara T; Hikita H; Kodama T; Tsunematsu H; Miyagi T; Hosui A; Ishida H; Tatsumi T; Kanto T; Hiramatsu N; Fujita N; Yoshimori T; Hayashi N
Int J Cancer; 2012 Aug; 131(3):548-57. PubMed ID: 21858812
[TBL] [Abstract][Full Text] [Related]
14. Effect of long non-coding RNA H19 on oxidative stress and chemotherapy resistance of CD133+ cancer stem cells via the MAPK/ERK signaling pathway in hepatocellular carcinoma.
Ding K; Liao Y; Gong D; Zhao X; Ji W
Biochem Biophys Res Commun; 2018 Jul; 502(2):194-201. PubMed ID: 29800569
[TBL] [Abstract][Full Text] [Related]
15. miR-23b-3p Modulating Cytoprotective Autophagy and Glutamine Addiction in Sorafenib Resistant HepG2, a Hepatocellular Carcinoma Cell Line.
Kaur R; Kanthaje S; Taneja S; Dhiman RK; Chakraborti A
Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011286
[TBL] [Abstract][Full Text] [Related]
16. Multiple Roles of Autophagy in the Sorafenib Resistance of Hepatocellular Carcinoma.
Sun T; Liu H; Ming L
Cell Physiol Biochem; 2017; 44(2):716-727. PubMed ID: 29169150
[TBL] [Abstract][Full Text] [Related]
17. Targeting and regulation of autophagy in hepatocellular carcinoma: revisiting the molecular interactions and mechanisms for new therapy approaches.
Hashemi M; Nadafzadeh N; Imani MH; Rajabi R; Ziaolhagh S; Bayanzadeh SD; Norouzi R; Rafiei R; Koohpar ZK; Raei B; Zandieh MA; Salimimoghadam S; Entezari M; Taheriazam A; Alexiou A; Papadakis M; Tan SC
Cell Commun Signal; 2023 Feb; 21(1):32. PubMed ID: 36759819
[TBL] [Abstract][Full Text] [Related]
18. PU.1/microRNA-142-3p targets ATG5/ATG16L1 to inactivate autophagy and sensitize hepatocellular carcinoma cells to sorafenib.
Zhang K; Chen J; Zhou H; Chen Y; Zhi Y; Zhang B; Chen L; Chu X; Wang R; Zhang C
Cell Death Dis; 2018 Feb; 9(3):312. PubMed ID: 29472524
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma.
Zhai B; Hu F; Jiang X; Xu J; Zhao D; Liu B; Pan S; Dong X; Tan G; Wei Z; Qiao H; Jiang H; Sun X
Mol Cancer Ther; 2014 Jun; 13(6):1589-98. PubMed ID: 24705351
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of cFLIP overcomes acquired resistance to sorafenib via reducing ER stress‑related autophagy in hepatocellular carcinoma.
Liu D; Fan Y; Li J; Cheng B; Lin W; Li X; Du J; Ling C
Oncol Rep; 2018 Oct; 40(4):2206-2214. PubMed ID: 30066934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
